Trial Profile
A Therapeutic-equivalence Study Comparing The Efficacy And Safety Of Intravenous Epoetin Hospira And Epoetin Alfa (Amgen) In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Epoetin zeta (Primary) ; Epoetin alfa
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Acronyms AiME - 01
- Sponsors Hospira; Pfizer
- 07 Aug 2018 The protocol was amended to require that patients be on stable IV epoetin alfa treatment for ≥4 weeks before randomization, the target level of hemoglobin was changed from 10.0-12.0 to 9.0-11.0 g/dl and the upper eligibility age range from 75 to 80 years, as per the results published in the Clinical Journal of The American Society of Nephrology: CJASN.
- 15 Apr 2014 New trial record